Paper41277909
Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies.
Rolfo CD and 11 others. J Liq Biopsy, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies. Papers, record 41277909. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41277909
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 41509815 | Corrigendum to "Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies" [J Liq Biopsy, 10 (2025), 100442]. | https://conductscience.org/library/papers/41509815 |
Source PubMed
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37702716 | Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37702716 | PubMed |
| 2 | 31335166 | An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. | JCO Clin Cancer Inform | 2019 | https://conductscience.org/library/papers/31335166 | PubMed |
| 3 | 35779872 | An overview of chemotoxicity and radiation toxicity in cancer therapy. | Adv Cancer Res | 2022 | https://conductscience.org/library/papers/35779872 | PubMed |
| 4 | 39352380 | Distinct landscape and clinical implications of therapy-related clonal hematopoiesis. | J Clin Invest | 2024 | https://conductscience.org/library/papers/39352380 | PubMed |
| 5 | 36869646 | Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. | Cancer | 2023 | https://conductscience.org/library/papers/36869646 | PubMed |
| 6 | 29330207 | Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29330207 | PubMed |
| 7 | 35008291 | Prediction of Chemotoxicity, Unplanned Hospitalizations and Early Death in Older Patients with Colorectal Cancer Treated with Chemotherapy. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/35008291 | PubMed |
| 8 | 31941831 | Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31941831 | PubMed |
| 9 | 30541742 | Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. | Cancer Res | 2019 | https://conductscience.org/library/papers/30541742 | PubMed |
| 10 | 39037536 | Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy. | Oncol Ther | 2024 | https://conductscience.org/library/papers/39037536 | PubMed |
| 11 | 40728234 | Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/40728234 | PubMed |
| 12 | 36265119 | Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples. | JCO Precis Oncol | 2022 | https://conductscience.org/library/papers/36265119 | PubMed |
| 13 | 32816849 | Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32816849 | PubMed |
| 14 | 33411622 | Comparisons of Real-World Time-to-Event End Points in Oncology Research. | JCO Clin Cancer Inform | 2021 | https://conductscience.org/library/papers/33411622 | PubMed |
| 15 | 35308944 | Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes. | AMIA Annu Symp Proc | 2021 | https://conductscience.org/library/papers/35308944 | PubMed |
| 16 | 30368012 | Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. | J Thorac Oncol | 2019 | https://conductscience.org/library/papers/30368012 | PubMed |
| 17 | 36208697 | Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. | Ann Oncol | 2023 | https://conductscience.org/library/papers/36208697 | PubMed |
| 18 | 37789101 | Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37789101 | PubMed |
| 19 | 36928816 | A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. | Nat Med | 2023 | https://conductscience.org/library/papers/36928816 | PubMed |
| 20 | 37814061 | ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. | Nat Med | 2023 | https://conductscience.org/library/papers/37814061 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42886888 | Plasma-Derived Genomic Instability Status and Rucaparib Outcomes in Metastatic Castration-Resistant Prostate Cancer: TRITON2. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/42886888 | PubMed |
| 42787936 | Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial. | J Liq Biopsy | 2026 | https://conductscience.org/library/papers/42787936 | PubMed |
| 42769118 | Cancer in a Drop: Liquid biopsy insights from AACR 2026. | J Liq Biopsy | 2026 | https://conductscience.org/library/papers/42769118 | PubMed |
| 42639369 | Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies. | Front Oncol | 2026 | https://conductscience.org/library/papers/42639369 | PubMed |
| 42539880 | Targeting tumor transition windows. | Explor Target Antitumor Ther | 2026 | https://conductscience.org/library/papers/42539880 | PubMed |
| 42395173 | Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors. | J Liq Biopsy | 2026 | https://conductscience.org/library/papers/42395173 | PubMed |
| 42243127 | Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy. | Nat Commun | 2026 | https://conductscience.org/library/papers/42243127 | PubMed |
| 42236890 | Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42236890 | PubMed |
| 42126023 | From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC? | Liver Int | 2026 | https://conductscience.org/library/papers/42126023 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41277909
GET https://conductscience.org/api/papers/v1/41277909/references?page=2